Evaxion announces completion of initial phases of collaboration with MSD

Evaxion Biotech (EVAX) announces the successful completion of the initial phases of its vaccine collaboration with MSD (MRK). The vaccine development project combines both organizations’ unique capabilities and know-how. Evaxion’s Chief Executive Officer Christian Kanstrup expresses enthusiasm, “In September last year, we announced a collaboration with a leading pharma company, and today we are proud to present that this collaborator is MSD. Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase. We strongly believe that this collaboration will further validate the power of our AI-Immunology platform and contribute to improving lives by designing unique vaccines addressing serious medical conditions.” Using Evaxion’s proprietary platform, AI-Immunology, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues. The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.